Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Employees - 12,
CEO - Mr. Martin A. Lehr,
Sector - Healthcare,
Country - US,
Market Cap - 64.50M
Altman ZScore(max is 10): 11.61, Piotroski Score(max is 10): 3, Working Capital: $95147551, Total Assets: $98126759, Retained Earnings: $-94779694, EBIT: -29923900, Total Liabilities: $2860497, Revenue: $0
AryaFin Target Price - $1.61 - Current Price $0.72 - Analyst Target Price $5.50
| Ticker | CNTX |
| Index | - |
| Curent Price | 0.72 |
| Change | 5.58% |
| Market Cap | 64.50M |
| Average Volume | 159.40K |
| Income | -26.73M |
| Sales | 0.00M |
| Book Value/Share | 1.06 |
| Cash/Share | 1.05 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 12 |
| Moving Avg 20days | -2.16% |
| Moving Avg 50days | -10.77% |
| Moving Avg 200days | -55.83% |
| Shares Outstanding | 89.70M |
| Earnings Date | Mar 20 AMC |
| Inst. Ownership | 47.51% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.68 |
| Price/Cash | 0.68 |
| Price/FCF | - |
| Quick Ratio | 35.55 |
| Current Ratio | 35.55 |
| Debt/Equity | 0.00 |
| Return on Assets | -46.81% |
| Return on Equity | -49.89% |
| Return on Investment | -28.02% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 47.27 |
| BETA(β) | 2.18 |
| From 52week Low | 30.73% |
| From 52week High | -73.85% |
| EPS | -0.53 |
| EPS next Year | -0.34 |
| EPS next Qtr | -0.06 |
| EPS this Year | 41.74% |
| EPS next 5 Year | -6.14% |
| EPS past 5 Year | 4.72% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 65.02% |
| Sales Y/Y | - |
| EPS Q/Q | 91.20% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 67.39% |
| ATR(14) | 0.11 |
| Perf Week | -2.38% |
| Perf Month | -14.61% |
| Perf Quarter | -31.52% |
| Perf Year | -47.13% |
| Perf YTD | -31.52% |
| Target Price | 5.50 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer